Medline Inc. Class A Common Stock (MDLN) Fair Value & Analysis
Healthcare · US · Market cap $70.3B · ISIN US58507V1070
What is Medline Inc. Class A Common Stock really worth?
Medline Inc. Class A Common Stock
MDLN · US
A solid business, but trading 21% above our fair value of $30.15.
Strengths
Risks
Fair value as of: Sep 5, 2026
From 26 valuation models · updated today
Share price −13.0% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- Solid but not exceptional quality (57/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range ($20.79 to $37.69) leaves room in how you read the outcome.
Price vs Fair Value (9 months)
White line = price, green steps = our fair value per fiscal year. As of Sep 5, 2026.
How to read this chart
9‑month range $32.58 – $49.99 · fair‑value band $20.79 – $37.69 · the $36.59 price screens above the $30.15 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Sep 5, 2026.
Analysis
Medline Inc. Class A Common Stock (MDLN) currently trades at $36.59, while our model-based Fair Value estimate is $30.15, implying the stock looks roughly 21.4% overvalued today. The Quality Score stands at 57/100 (solid quality), in the Healthcare sector. Bull case: the Growth DCF group reads highest at a median of $42.98 per share, and 13 of the 26 models we run sit above the $36.59 price. Bear case: the Asset-Based group reads lowest at $8.51, and 13 of the 26 models stay below the price. Evidence for this calculation is medium.
Over the trailing twelve months, Medline Inc. Class A Common Stock generated revenue of $29.1B at a net margin of 3.3%. Revenue grew 10.7% year over year. It earns a return on equity of 6.1%. Net debt stands at $10.6B. Fundamentals as of Sep 5, 2026
Our scenario range runs from $20.79 (bear case) to $37.69 (bull case); at $36.59, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 28% below its 52-week high and 12% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −46% fair-value upside, at −18%, MDLN screens cheaper than that median.
Fair Value models
This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly $0.7746 per share, which is 2.6 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 26 models by family
Widest divergence: Growth DCF ($42.98) versus Asset-Based ($8.51). Highest evidence: FCF DCF (73).
Notify me when MDLN reaches fair value
Put MDLN on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Sep 5, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 55 · Market factors (momentum, volatility) 31
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. It operates through two segments: Medline Brand and Supply Chain Solutions.
Full company description
Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. It operates through two segments: Medline Brand and Supply Chain Solutions. The Medline Brand segment procures and manufactures products from three product categories include surgical solutions, front line care, and laboratory and diagnostics. Its front line care offers med-surg products for patient-facing needs, including wound care products, exam gloves, skin care and incontinence products, environment cleaning supplies, textiles, hand sanitizer, durable medical equipment, patient plastics, and decolonization and infection control products. Its surgical solutions provide operating room and perioperative environment product solutions, including surgical procedure trays, drapes and gowns, personal protective equipment, sterile wraps, surgical instruments, surgeon's gloves, procedure kits, and orthopedic implants. Its laboratory and diagnostics offer laboratory and diagnostic product solutions, including point of care testing, analyzers and instrumentation, lab and diagnostic consumables, diagnostic instruments, vital signs monitors, and anatomic pathology and phlebotomy products. It provides its products to domestic and international consumers. The Supply Chain Solutions segment procures and distributes a variety of third-party products from national brands. It provides logistics and supply chain optimization services to domestic and international consumers. It also provides supply chain optimization services, such as consulting engagements, outsourced warehouse and technology management, put-away-ready packaging, third-party logistics, inventory rationalization, and route planning. The company was founded in 1966 and is based in Northfield, Illinois.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2025 · reported fiscal years
Medline Inc. Class A Common Stock reported revenue of $28.4B in FY2025 versus $21.4B in FY2022, a compound +9.9%/yr. Reported net income was $1.2B in FY2025.
MDLN screens 21% overvalued. Compare with Intuitive Surgical, Inc →
Earlier news
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.
- Medline (MDLN) Q2 2026 Earnings Call Transcript
- NASDAQ: MDLN Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Medline Inc. (NASDAQ: MDLN) Investors to Contact the Firm
- Medline Q2 Earnings Call Highlights
Peer Group
Medical Instruments & Supplies · 194 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Sep 5, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $367.07 | $150.04 | −59% |
| EssilorLuxottica Société anonyme EL | €160.35 | €94.93 | −41% |
| Becton, Dickinson and Company BDX | $187.12 | $100.46 | −46% |
| Alcon Inc ALC | $72.23 | $39.78 | −45% |
| ResMed Inc RMD | A$33.19 | A$26.23 | −21% |
| West Pharmaceutical Services, Inc WST | $337.47 | $141.58 | −58% |
| Sartorius Stedim Biotech S.A DIM | €197.70 | €48.88 | −75% |
| Straumann Holding STMN | CHF 97.38 | CHF 47.31 | −51% |
| Sartorius Aktiengesellschaft SRT3 | €253.50 | €63.30 | −75% |
| Coloplast A/S COLOB | kr 435.80 | kr 382.22 | −12% |
Compare Medline Inc. Class A Common Stock with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Medline Inc. Class A Common Stock (MDLN) overvalued or undervalued?
What is the fair value of MDLN?
What is the quality score of MDLN?
What is the revenue of Medline Inc. Class A Common Stock (MDLN)?
What is the net profit margin of MDLN?
Does Medline Inc. Class A Common Stock pay a dividend?
Watch Medline Inc. Class A Common Stock in the live analysis
One click puts Medline Inc. Class A Common Stock on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.